Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The kallikrein-kinin system: current and future pharmacological targets Moreau ME; Garbacki N; Molinaro G; Brown NJ; Marceau F; Adam AJ Pharmacol Sci 2005[Sep]; 99 (1): 6-38The kallikrein-kinin system is an endogenous metabolic cascade, triggering of which results in the release of vasoactive kinins (bradykinin-related peptides). This complex system includes the precursors of kinins known as kininogens and mainly tissue and plasma kallikreins. The pharmacologically active kinins, which are often considered as either proinflammatory or cardioprotective, are implicated in many physiological and pathological processes. The interest of the various components of this multi-protein system is explained in part by the multiplicity of its pharmacological activities, mediated not only by kinins and their receptors, but also by their precursors and their activators and the metallopeptidases and the antiproteases that limit their activities. The regulation of this system by serpins and the wide distribution of the different constituents add to the complexity of this system, as well as its multiple relationships with other important metabolic pathways such as the renin-angiotensin, coagulation, or complement pathways. The purpose of this review is to summarize the main properties of this kallikrein-kinin system and to address the multiple pharmacological interventions that modulate the functions of this system, restraining its proinflammatory effects or potentiating its cardiovascular properties.|Angioedema/drug therapy/genetics[MESH]|Angiotensin-Converting Enzyme Inhibitors/*pharmacology/therapeutic use[MESH]|Animals[MESH]|Aprotinin/pharmacology/therapeutic use[MESH]|Bradykinin B2 Receptor Antagonists[MESH]|Bradykinin/analogs & derivatives/pharmacology/therapeutic use[MESH]|Cardiovascular Diseases/drug therapy/genetics[MESH]|Complement C1 Inactivator Proteins/deficiency/genetics[MESH]|Complement C1 Inhibitor Protein[MESH]|Humans[MESH]|Inflammation/drug therapy/genetics[MESH]|Kallikrein-Kinin System/*drug effects/genetics/*physiology[MESH]|Kallikreins/antagonists & inhibitors/*metabolism[MESH]|Kidney Diseases/drug therapy/genetics[MESH]|Kinins/agonists/antagonists & inhibitors/*metabolism[MESH]|Neprilysin/antagonists & inhibitors/metabolism[MESH]|Peptidyl-Dipeptidase A/metabolism[MESH]|Polymorphism, Genetic[MESH]|Pyridines/pharmacology/therapeutic use[MESH]|Randomized Controlled Trials as Topic[MESH]|Receptor, Bradykinin B1/genetics/metabolism[MESH]|Receptor, Bradykinin B2/genetics/metabolism[MESH]|Serpins/deficiency/genetics[MESH]|Thiazepines/pharmacology/therapeutic use[MESH] |
